We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACGN
326
CALL
DELISTED
Aceragen Inc
ACGN
– –
-27
Closed -$1.61K
STAB
327
DELISTED
Statera Biopharma, Inc. Common Stock
STAB
– –
-18,858
Closed -$108
ARNA
328
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-13
Closed -$45
DRNA
329
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-145,919
Closed -$2.4K
ACHN
330
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-296
Closed -$363
HZNP
331
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-331
Closed -$427
KERX
332
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-250
Closed -$354
WGBS
333
DELISTED
WaferGen Bio-systems, Inc.
WGBS
– –
-117,051
Closed -$1.76K
ARIA
334
CALL
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-259
Closed -$178
AEGR
335
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-500
Closed -$1.05K
TBRA
336
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-95,839
Closed -$788
CPXX
337
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-140,234
Closed -$275
ALXA
338
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
– –
-2,040
Closed -$304
MDGN.WS
339
DELISTED
MEDGENICS INC WT PUR COM EXP 03/31/16
MDGN.WS
– –
-1,271,240
Closed -$922
ASPX
340
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-50,000
Closed -$2.62K
NPSP
341
CALL
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-594
Closed -$2.13K
NPSP
342
DELISTED
NPS PHARMACEUTICALS INC
NPSP
– –
-41,670
Closed -$1.49K
AUXL
343
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
– –
-3,964
Closed -$13.6K
CBST
344
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-873
Closed -$8.79K
CTIC
345
PUT
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-26
Closed -$60
RXII
346
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
– –
-139
Closed -$21
COV
347
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-65,537
Closed -$6.7K
COV
348
PUT
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
– –
-1,911
Closed -$19.5K
CELG
349
CALL
DELISTED
Celgene Corp
CELG
– –
-280
Closed -$3.13K
SHPG
350
DELISTED
Shire pic
SHPG
– –
-9,652
Closed -$2.05K
11 12 13
14
15

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.